Condition category
Nutritional, Metabolic, Endocrine
Date applied
09/08/2013
Date assigned
27/09/2013
Last edited
09/04/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
In this study, we are looking at the adults with type 2 diabetes and metabolic syndrome to assess the effect of the Ma-Pi 2 Macrobiotic Diet on metabolic control. Recent studies have shown that a diet high in whole cereals, vegetables and legumes while low in simple carbohydrates, refined cereals, fat and food of animal origin could be helpful in type 2 diabetes mellitus management. These results seemed to be confirmed by recent advances in the exploration and modeling of the gut microbiota. Our goal is to assess the effect of a diet with these characteristics: the Ma-Pi 2 macrobiotic diet. The study's findings should help to improve the well-being of diabetic patients with metabolic syndrome and to determine a new dietary approach to these diseases and related complications.

Who can participate?
This study aims to recruit 58 type 2 diabetic patients with metabolic syndrome of both genders, aged 45 to75 years.

What does the study involve?
Eligible patients will be enrolled in the study and randomly allocated to one of two groups to receive either the Ma-Pi 2 macrobiotic diet or a conventional standard diet. For 21 days they will be staying in two separate hotels in the same area in Italy, where they will receive all daily meals according to their group allocation. Blood tests and glucose level measurements will be carried out at the start of the study and after 21 days.

What are the possible benefits and risks of participating?
There may be immediate direct benefits to the subjects participating as described in previous studies such as reduction in their blood glucose levels and weight loss. The main risk could be dropping of glucose levels drastically and to avoid it they will be strictly monitored by the doctors and specialists involved.

Where is the study run from?
This study is run from the Endocrinology Area of the University of Campus Biomedico of Rome, Italy.

When is study starting and how long is it expected to run for?
The recruitment started in February 2013 and finished in April 2013. The second follow-up will finish in September 2013.

Who is funding the study?
The study is funded by UPM Un Punto Macrobiotico International Association, Italy.

Who is the main contact?
Professor Paolo Pozzilli p.pozzilli@unicampus.it
Dr Andreea Soare a.soare@unicampus.it

Trial website

Contact information

Type

Scientific

Primary contact

Prof Paolo Pozzilli

ORCID ID

Contact details

Endocrinology Area
University of Campus Bio-Medico
Rome
00128
Italy
+39 06 22541 9160
p.pozzilli@unicampus.it

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Prot. 11/13

Study information

Scientific title

A randomised controlled trial to assess the short-term effect of the macrobiotic diet Ma-Pi 2 in patients with type 2 diabetes and metabolic syndrome

Acronym

MADIAB

Study hypothesis

This study is designed to determine whether short-term administration of the macrobiotic Ma-Pi 2 diet improves metabolic control (improvement in glycemic profile, blood glucose levels, HbA1c, HOMA IR and plasma lipid fractions) in type 2 diabetic subjects with metabolic syndrome compared with the standard diet recommended for diabetic patients (according to the Italian Society of Diabetology and Italian Association of Diabetologists guidelines).

The null hypothesis is that there will be no reduction of studied metabolic parameters or that there will be no difference in metabolic improvement between the two dietary treatment groups.

Ethics approval

Ethical Committee of University of Campus Biomedico, Rome, 26/02/2013, ref: Prot.n. 11/13 PAR ComEt CBM

Study design

Randomized controlled single-centre two parallel groups trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Other

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Type 2 diabetes mellitus and metabolic syndrome

Intervention

The subjects enrolled in the study are randomized and consequently divided into two homogeneous groups to receive the two dietary treatments. Over a period of 21 days they are lodged in two separate hotels in the same area in Italy, where they receive all daily meals (respectively Ma-Pi 2 Macrobiotic meals and recommended standard diet for diabetic patients).
Blood sample analyses, antropometrical and glucose profile measurements will be carried out at basal and after 21 days of the dietary interventions.
Since 27/04/2013 the protocol was integrated by a supplementary follow-up of 3 and 6 months.

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

The primary endpoint is to determine in the two study groups the percentage rate reduction of the following parameters: HbA1c, fasting blood glucose, 2 hours post-lunch blood glucose, HOMA IR, total cholesterol, cholesterol - low density lipoprotein (LDL), triglyceride, BMI, waist and hip circumference. We compare the reduction of these parameters obtained in the two study groups (Ma-Pi 2 diet vs recommended standard diet for diabetic patients according to the Italian Society of Diabetology and Italian Association of Diabetologists guidelines).

1. For HbA1c at time 0 (before dietary intervention on 05/04/2013) and after 21 days of the dietary interventions (on 27/04/2013), and then for the supplementary follow-up at 27/07/2013 and 27/10/2013.
2. For HOMA IR, total cholesterol, cholesterol - low density lipoprotein (LDL), triglyceride, BMI, waist and hip circunference at time 0 (before dietary intervention on 05/04/2013) and after 21 days of the dietary interventions (on 27/04/2013), and then for the supplementary follow-up at 27/07/2013 and 27/10/2013.
3. For fasting and 2 hours post-lunch blood glucose: daily from the 05/07/2013 to the 27/04/2012, and then for the supplementary follow-up at 27/07/2013 and 27/10/2013.

Secondary outcome measures

1. Changes in renal function biochemical parameters (blood urea nitrogen, uric acid)
2. Changes in insulin-like growth factor (IGF1)
3. Changes in markers of inflammation (PCR, WBC, IL-6, TNF-alpha)
4. Changes in gut microbiota composition
5. Changes in body composition

Changes in renal function biochemical parameters (blood urea nitrogen, uric acid), changes in insulin-like growth factor (IGF1), changes in markers of inflammation (PCR, WBC, IL-6, TNF-alpha), changes in gut microbiota composition, changes in body composition: at time 0 (before dietary intervention on 05/04/2013) and after 21 days of the dietary interventions (on 27/04/2013).

Overall trial start date

27/02/2013

Overall trial end date

27/09/2013

Reason abandoned

Eligibility

Participant inclusion criteria

1. Subjects affected by type 2 diabetes and metabolic syndrome
2. Subjects of both genders, aged 40 to 80 years
3. Subjects who able to sign the informed consent and to follow the study requests
4. Subjects with body mass index (BMI) >25 kg/m2 but <45 kg/m2
5. DM treated with diet only or oral hypoglycemic agents [sulfonylureas (SU), metformin (MF)] and / with GLP-1 (injecting or orally) alone and/or in combination but not insulin therapy

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

58

Participant exclusion criteria

1. Patients affected by type 1 diabetes mellitus or type 2 diabetes on insulin therapy
2. Patients with serious underlying medical conditions such as cancer, severe infections, severe psychiatric disorders
3. Patients who have done other clinical trials in the prior three months of this study
4. Known or suspected hypersensitivity to one or more ingredients of the diets
5. Patients undergoing cortico-therapy or other drugs that may interfere with the metabolism of carbohydrates
6. Patients undergoing antibiotic therapy

Recruitment start date

27/02/2013

Recruitment end date

01/04/2013

Locations

Countries of recruitment

Italy

Trial participating centre

University of Campus Bio-Medico
Rome
00128
Italy

Sponsor information

Organisation

UPM Un Punto Macrobiotico International Association (Italy)

Sponsor details

Via San Nicola
9
Tolentino
62029
Italy
+39 07 3396 1019
upm@unpuntomacrobiotico.it

Sponsor type

Charity

Website

Funders

Funder type

Charity

Funder name

UPM Un Punto Macrobiotico International Association (Italy)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/25302069
2015 post hoc analysis in: http://www.ncbi.nlm.nih.gov/pubmed/25852946

Publication citations

  1. Results

    Soare A, Khazrai YM, Del Toro R, Roncella E, Fontana L, Fallucca S, Angeletti S, Formisano V, Capata F, Ruiz V, Porrata C, Skrami E, Gesuita R, Manfrini S, Fallucca F, Pianesi M, Pozzilli P, The effect of the macrobiotic Ma-Pi 2 diet vs. the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial., Nutr Metab (Lond), 2014, 11, 39, doi: 10.1186/1743-7075-11-39.

  2. Results

    A Soare, R Del Toro, E Roncella, YM Khazrai, S Angeletti, L Dugo, S Fallucca, L Fontana, M Altomare, V Formisano, F Capata, R Gesuita, S Manfrini, F Fallucca, Mario Pianesi, Paolo Pozzilli, for the MADIAB Group, The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial , BMJ Open Diab Res Care , 2015, 3, e000079, doi: 10.1136/bmjdrc-2014-000079.

Additional files

Editorial Notes